285 related articles for article (PubMed ID: 36331947)
41. Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM).
Capelli G; De Simone I; Spolverato G; Cinquini M; Moschetti I; Lonardi S; Masi G; Carlomagno C; Corsi D; Luppi G; Gambacorta MA; Valvo F; Cannizzaro R; Grillo F; Barbaro B; Restivo A; Messina M; Pastorino A; Aschele C; Pucciarelli S
J Gastrointest Surg; 2020 Sep; 24(9):2150-2159. PubMed ID: 32394125
[TBL] [Abstract][Full Text] [Related]
42. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
43. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
44. Local resection versus radical resection after neoadjuvant chemoradiotherapy for patients with locally advanced rectal cancer: a propensity-score matched cohort analysis.
Wang G; Yao K; Yang Y; Chen H; Tang Z; Ye J; Fu M; Xue X; Shen Q; Tang H; Guo Y; Huang Y
BMC Gastroenterol; 2023 Jun; 23(1):205. PubMed ID: 37312044
[TBL] [Abstract][Full Text] [Related]
45. [Prognosis and complications of local excision for rectal cancer after neoadjuvant chemoradiotherapy].
Li YH; Qiu XY; Lin GL; Zhou JL; Xiao Y; Qiu HZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):344-351. PubMed ID: 33878824
[No Abstract] [Full Text] [Related]
46. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
[TBL] [Abstract][Full Text] [Related]
47. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
48. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer.
He F; Yu L; Ding Y; Li ZH; Wang J; Zheng J; Chen HY; Liu S; Pang XL; Ajani JA; Wan XB
Cancer Sci; 2020 Nov; 111(11):4205-4217. PubMed ID: 32860448
[TBL] [Abstract][Full Text] [Related]
49. A dynamic nomogram for predicting pathologic complete response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Wang G; Li J; Huang Y; Guo Y
Cancer Med; 2024 Jun; 13(11):e7251. PubMed ID: 38819440
[TBL] [Abstract][Full Text] [Related]
50. Standard versus longer interval of radical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A 20-year single-center experience & propensity-score matching.
Khamzina S; Lee J; Ryoo SB; Kim MJ; Park JW; Kang HC; Chie EK; Lee DW; Han SW; Kim TY; Jeong SY; Park KJ
J Surg Oncol; 2023 Jan; 127(1):119-131. PubMed ID: 36169163
[TBL] [Abstract][Full Text] [Related]
51. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single-institution study with propensity score-matched comparative analysis.
Sun XY; Cai SH; Xu L; Luo D; Qiu HZ; Wu B; Lin GL; Lu JY; Zhang GN; Xiao Y
Asia Pac J Clin Oncol; 2020 Jun; 16(3):142-149. PubMed ID: 32031326
[TBL] [Abstract][Full Text] [Related]
53. MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
Jia X; Xie P; Bi L; Meng X; Wang Z; Hong N; Wang Y
Br J Radiol; 2021 Apr; 94(1120):20201221. PubMed ID: 33591799
[TBL] [Abstract][Full Text] [Related]
54. Surgical and short-term oncological safety of total neoadjuvant therapy in high-risk locally advanced rectal cancer.
Ng YY; Seow-En I; Chok AY; Lee TS; Palanisamy P; Tan EK
ANZ J Surg; 2024 Feb; 94(1-2):175-180. PubMed ID: 37849414
[TBL] [Abstract][Full Text] [Related]
55. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching.
Zhang Y; Sun Y; Xu Z; Chi P; Lu X
Eur J Surg Oncol; 2017 Aug; 43(8):1440-1446. PubMed ID: 28502421
[TBL] [Abstract][Full Text] [Related]
56. Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis.
Du D; Su Z; Wang D; Liu W; Wei Z
Clin Colorectal Cancer; 2018 Mar; 17(1):13-24. PubMed ID: 29153429
[TBL] [Abstract][Full Text] [Related]
57. Multimodal assessment after total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer accurately predicts complete responders.
Özoran E; Özata İH; Uymaz DS; Omarov N; Bozkurt E; Tüfekçi T; Karahan SN; Gürbüz B; Selçukbiricik F; Bölükbaşı Y; Taşkın OÇ; Gürses B; Rencüzoğulları A; Buğra D; Balık E
Int J Colorectal Dis; 2023 Sep; 38(1):229. PubMed ID: 37707664
[TBL] [Abstract][Full Text] [Related]
58. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
[TBL] [Abstract][Full Text] [Related]
59. Impact of adjuvant chemotherapy on survival after pathological complete response in rectal cancer: a meta-analysis of 31,558 patients.
de Moraes FCA; Kelly FA; Souza MEC; Burbano RMR
Int J Colorectal Dis; 2024 Jun; 39(1):96. PubMed ID: 38913175
[TBL] [Abstract][Full Text] [Related]
60. Is Total Neoadjuvant Treatment Beneficial for Locally Advanced Rectal Cancer? A Meta-Analysis of Randomized Controlled Trials.
Wu HQ; Li J; Miao JD; Li JW
Oncology; 2024; 102(5):399-413. PubMed ID: 37926087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
